-
2
-
-
84875982804
-
The changing epidemiology of methicillin-resistant Staphylococcus aureus in the United States: A national observational study
-
E.Y. Klein, L. Sun, D.L. Smith, and R. Laxminarayan The changing epidemiology of methicillin-resistant Staphylococcus aureus in the United States: a national observational study Am J Epidemiol 177 2013 666 674
-
(2013)
Am J Epidemiol
, vol.177
, pp. 666-674
-
-
Klein, E.Y.1
Sun, L.2
Smith, D.L.3
Laxminarayan, R.4
-
3
-
-
44149113314
-
Epidemiology of methicillin-resistant Staphylococcus aureus
-
H.W. Boucher, and G.R. Corey Epidemiology of methicillin-resistant Staphylococcus aureus Clin Infect Dis 46 Suppl 5 2008 S344 S349
-
(2008)
Clin Infect Dis
, vol.46
, Issue.SUPPL. 5
-
-
Boucher, H.W.1
Corey, G.R.2
-
5
-
-
29244453639
-
Vancomycin: A 50-year reassessment
-
R.C. Moellering Jr. Vancomycin: a 50-year reassessment Clin Infect Dis 42 Suppl 1 2006 S3 S4
-
(2006)
Clin Infect Dis
, vol.42
, Issue.SUPPL. 1
-
-
Moellering, Jr.R.C.1
-
6
-
-
29244437540
-
Vancomycin: A history
-
D.P. Levine Vancomycin: a history Clin Infect Dis 42 Suppl 1 2006 S5 S12
-
(2006)
Clin Infect Dis
, vol.42
, Issue.SUPPL. 1
-
-
Levine, D.P.1
-
7
-
-
62449183879
-
Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists
-
M. Rybak, B. Lomaestro, J.C. Rotschafer, R. Moellering Jr., W. Craig, and M. Billeter et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists Am J Health Syst Pharm 66 2009 82 98
-
(2009)
Am J Health Syst Pharm
, vol.66
, pp. 82-98
-
-
Rybak, M.1
Lomaestro, B.2
Rotschafer, J.C.3
Moellering, Jr.R.4
Craig, W.5
Billeter, M.6
-
8
-
-
0033630535
-
Excessive use of vancomycin: A successful intervention strategy at an academic medical center
-
C.D. Hamilton, R. Drew, S.W. Janning, J.K. Latour, and S. Hayward Excessive use of vancomycin: a successful intervention strategy at an academic medical center Infect Control Hosp Epidemiol 21 2000 42 45
-
(2000)
Infect Control Hosp Epidemiol
, vol.21
, pp. 42-45
-
-
Hamilton, C.D.1
Drew, R.2
Janning, S.W.3
Latour, J.K.4
Hayward, S.5
-
9
-
-
33144473431
-
Bad bugs need drugs: An update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America
-
G.H. Talbot, J. Bradley, J.E. Edwards Jr., D. Gilbert, M. Scheld, and J.G. Bartlett Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America Clin Infect Dis 42 2006 657 668
-
(2006)
Clin Infect Dis
, vol.42
, pp. 657-668
-
-
Talbot, G.H.1
Bradley, J.2
Edwards, Jr.J.E.3
Gilbert, D.4
Scheld, M.5
Bartlett, J.G.6
-
10
-
-
57749107808
-
Bad bugs, no drugs: No ESKAPE! An update from the Infectious Diseases Society of America
-
H.W. Boucher, G.H. Talbot, J.S. Bradley, J.E. Edwards, D. Gilbert, and L.B. Rice et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America Clin Infect Dis 48 2009 1 12
-
(2009)
Clin Infect Dis
, vol.48
, pp. 1-12
-
-
Boucher, H.W.1
Talbot, G.H.2
Bradley, J.S.3
Edwards, J.E.4
Gilbert, D.5
Rice, L.B.6
-
11
-
-
0033517574
-
Time to register randomised trials. The case is now unanswerable
-
R. Horton, and R. Smith Time to register randomised trials. The case is now unanswerable BMJ 319 1999 865 866
-
(1999)
BMJ
, vol.319
, pp. 865-866
-
-
Horton, R.1
Smith, R.2
-
12
-
-
0033547647
-
Registering clinical trials
-
A. Tonks Registering clinical trials BMJ 319 1999 1565 1568
-
(1999)
BMJ
, vol.319
, pp. 1565-1568
-
-
Tonks, A.1
-
13
-
-
29544449337
-
Trial registration at ClinicalTrials.gov between May and October 2005
-
D.A. Zarin, T. Tse, and N.C. Ide Trial registration at ClinicalTrials.gov between May and October 2005 N Engl J Med 353 2005 2779 2787
-
(2005)
N Engl J Med
, vol.353
, pp. 2779-2787
-
-
Zarin, D.A.1
Tse, T.2
Ide, N.C.3
-
14
-
-
84896491689
-
-
And Drug Administration Amendments Act Of 2007 F.
-
Food and Drug Administration Amendments Act of 2007 Public Law: 110th Congress 2007
-
(2007)
Public Law: 110th Congress
-
-
-
15
-
-
40449088049
-
Medicine. Moving toward transparency of clinical trials
-
D.A. Zarin, and T. Tse Medicine. Moving toward transparency of clinical trials Science 319 2008 1340 1342
-
(2008)
Science
, vol.319
, pp. 1340-1342
-
-
Zarin, D.A.1
Tse, T.2
-
16
-
-
79955752771
-
Pharmacokinetics and safety of single, multiple, and loading doses of fusidic acid in healthy subjects
-
J.G. Still, K. Clark, T.P. Degenhardt, D. Scott, P. Fernandes, and M.J. Gutierrez Pharmacokinetics and safety of single, multiple, and loading doses of fusidic acid in healthy subjects Clin Infect Dis 52 Suppl 7 2011 S504 S512
-
(2011)
Clin Infect Dis
, vol.52
, Issue.SUPPL. 7
-
-
Still, J.G.1
Clark, K.2
Degenhardt, T.P.3
Scott, D.4
Fernandes, P.5
Gutierrez, M.J.6
-
17
-
-
84866313208
-
In vitro and in vivo characterization of CB-183,315, a novel lipopeptide antibiotic for treatment of Clostridium difficile
-
C.T. Mascio, L.I. Mortin, K.T. Howland, A.D. Van Praagh, S. Zhang, and A. Arya et al. In vitro and in vivo characterization of CB-183,315, a novel lipopeptide antibiotic for treatment of Clostridium difficile Antimicrob Agents Chemother 56 2012 5023 5030
-
(2012)
Antimicrob Agents Chemother
, vol.56
, pp. 5023-5030
-
-
Mascio, C.T.1
Mortin, L.I.2
Howland, K.T.3
Van Praagh, A.D.4
Zhang, S.5
Arya, A.6
-
18
-
-
84864386108
-
Mechanism of action of and mechanism of reduced susceptibility to the novel anti-Clostridium difficile compound LFF571
-
J.A. Leeds, M. Sachdeva, S. Mullin, J. Dzink-Fox, and M.J. Lamarche Mechanism of action of and mechanism of reduced susceptibility to the novel anti-Clostridium difficile compound LFF571 Antimicrob Agents Chemother 56 2012 4463 4465
-
(2012)
Antimicrob Agents Chemother
, vol.56
, pp. 4463-4465
-
-
Leeds, J.A.1
Sachdeva, M.2
Mullin, S.3
Dzink-Fox, J.4
Lamarche, M.J.5
-
19
-
-
84868254408
-
Fecal microbiota transplantation in relapsing Clostridium difficile infection
-
F. Rohlke, and N. Stollman Fecal microbiota transplantation in relapsing Clostridium difficile infection Therap Adv Gastroenterol 5 2012 403 420
-
(2012)
Therap Adv Gastroenterol
, vol.5
, pp. 403-420
-
-
Rohlke, F.1
Stollman, N.2
-
20
-
-
84857183374
-
Antimicrobial activity of the investigational pleuromutilin compound BC-3781 tested against Gram-positive organisms commonly associated with acute bacterial skin and skin structure infections
-
H.S. Sader, D.J. Biedenbach, S. Paukner, Z. Ivezic-Schoenfeld, and R.N. Jones Antimicrobial activity of the investigational pleuromutilin compound BC-3781 tested against Gram-positive organisms commonly associated with acute bacterial skin and skin structure infections Antimicrob Agents Chemother 56 2012 1619 1623
-
(2012)
Antimicrob Agents Chemother
, vol.56
, pp. 1619-1623
-
-
Sader, H.S.1
Biedenbach, D.J.2
Paukner, S.3
Ivezic-Schoenfeld, Z.4
Jones, R.N.5
-
23
-
-
0242291985
-
Why is big Pharma getting out of antibacterial drug discovery?
-
S.J. Projan Why is big Pharma getting out of antibacterial drug discovery? Curr Opin Microbiol 6 2003 427 430
-
(2003)
Curr Opin Microbiol
, vol.6
, pp. 427-430
-
-
Projan, S.J.1
-
24
-
-
2342595765
-
Trends in antimicrobial drug development: Implications for the future
-
B. Spellberg, J.H. Powers, E.P. Brass, L.G. Miller, and J.E. Edwards Jr. Trends in antimicrobial drug development: implications for the future Clin Infect Dis 38 2004 1279 1286
-
(2004)
Clin Infect Dis
, vol.38
, pp. 1279-1286
-
-
Spellberg, B.1
Powers, J.H.2
Brass, E.P.3
Miller, L.G.4
Edwards, Jr.J.E.5
-
25
-
-
12944302098
-
Lack of development of new antimicrobial drugs: A potential serious threat to public health
-
European Society of Clinical Microbiology and Infectious Diseases
-
S.R. Norrby, C.E. Nord, R. Finch European Society of Clinical Microbiology and Infectious Diseases Lack of development of new antimicrobial drugs: a potential serious threat to public health Lancet Infect Dis 5 2005 115 119
-
(2005)
Lancet Infect Dis
, vol.5
, pp. 115-119
-
-
Norrby, S.R.1
Nord, C.E.2
Finch, R.3
-
26
-
-
2342534392
-
Development of drugs for antimicrobial-resistant pathogens
-
J.H. Powers Development of drugs for antimicrobial-resistant pathogens Curr Opin Infect Dis 16 2003 547 551
-
(2003)
Curr Opin Infect Dis
, vol.16
, pp. 547-551
-
-
Powers, J.H.1
-
27
-
-
84878297844
-
Is it time to replace vancomycin in the treatment of methicillin- resistant Staphylococcus aureus infections?
-
S.J. van Hal, and V.G. Fowler Jr. Is it time to replace vancomycin in the treatment of methicillin-resistant Staphylococcus aureus infections? Clin Infect Dis 56 2013 1779 1788
-
(2013)
Clin Infect Dis
, vol.56
, pp. 1779-1788
-
-
Van Hal, S.J.1
Fowler, Jr.V.G.2
-
28
-
-
84855484682
-
New insights into meticillin-resistant Staphylococcus aureus (MRSA) pathogenesis, treatment and resistance
-
I.M. Gould, M.Z. David, S. Esposito, J. Garau, G. Lina, and T. Mazzei et al. New insights into meticillin-resistant Staphylococcus aureus (MRSA) pathogenesis, treatment and resistance Int J Antimicrob Agents 39 2012 96 104
-
(2012)
Int J Antimicrob Agents
, vol.39
, pp. 96-104
-
-
Gould, I.M.1
David, M.Z.2
Esposito, S.3
Garau, J.4
Lina, G.5
Mazzei, T.6
-
29
-
-
70349934707
-
Vancomycin in combination with other antibiotics for the treatment of serious methicillin-resistant Staphylococcus aureus infections
-
S. Deresinski Vancomycin in combination with other antibiotics for the treatment of serious methicillin-resistant Staphylococcus aureus infections Clin Infect Dis 49 2009 1072 1079
-
(2009)
Clin Infect Dis
, vol.49
, pp. 1072-1079
-
-
Deresinski, S.1
-
33
-
-
70049105657
-
Bad bugs, no drugs: No ESCAPE revisited
-
L.R. Peterson Bad bugs, no drugs: no ESCAPE revisited Clin Infect Dis 49 2009 992 993
-
(2009)
Clin Infect Dis
, vol.49
, pp. 992-993
-
-
Peterson, L.R.1
-
34
-
-
84878278251
-
10 × '20 progress - Development of new drugs active against Gram-negative bacilli: An update from the Infectious Diseases Society of America
-
H.W. Boucher, G.H. Talbot, D.K. Benjamin Jr., J. Bradley, R.J. Guidos, and R.N. Jones et al. 10 × '20 progress - development of new drugs active against Gram-negative bacilli: an update from the Infectious Diseases Society of America Clin Infect Dis 56 2013 1685 1694
-
(2013)
Clin Infect Dis
, vol.56
, pp. 1685-1694
-
-
Boucher, H.W.1
Talbot, G.H.2
Benjamin, Jr.D.K.3
Bradley, J.4
Guidos, R.J.5
Jones, R.N.6
-
35
-
-
77950255824
-
The 10 × '20 Initiative: Pursuing a global commitment to develop 10 new antibacterial drugs by 2020
-
Diseases Society Of America I.
-
Infectious Diseases Society of America The 10 × '20 Initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020 Clin Infect Dis 50 2010 1081 1083
-
(2010)
Clin Infect Dis
, vol.50
, pp. 1081-1083
-
-
-
36
-
-
84896494408
-
-
Nabriva Therapeutics Vienna, Austria
-
® [Phase II] 2013 Nabriva Therapeutics Vienna, Austria
-
(2013)
® [Phase II]
-
-
-
37
-
-
84856718514
-
Fidaxomicin: A novel macrocyclic antibiotic approved for treatment of Clostridium difficile infection
-
A.A. Venugopal, and S. Johnson Fidaxomicin: a novel macrocyclic antibiotic approved for treatment of Clostridium difficile infection Clin Infect Dis 54 2012 568 574
-
(2012)
Clin Infect Dis
, vol.54
, pp. 568-574
-
-
Venugopal, A.A.1
Johnson, S.2
-
40
-
-
84896489971
-
Tolevamer less effective than standard therapies for C. Difficile-associated diarrhea
-
C. Berrie Tolevamer less effective than standard therapies for C. difficile-associated diarrhea Medscape Medical News April 24, 2008
-
(2008)
Medscape Medical News
-
-
Berrie, C.1
-
41
-
-
84856969539
-
Fecal microbiota transplantation and emerging applications
-
T.J. Borody, and A. Khoruts Fecal microbiota transplantation and emerging applications Nat Rev Gastroenterol Hepatol 9 2012 88 96
-
(2012)
Nat Rev Gastroenterol Hepatol
, vol.9
, pp. 88-96
-
-
Borody, T.J.1
Khoruts, A.2
-
42
-
-
77953558104
-
Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft-tissue infections proven to be caused by methicillin-resistant Staphylococcus aureus
-
K.M. Itani, M.S. Dryden, H. Bhattacharyya, M.J. Kunkel, A.M. Baruch, and J.A. Weigelt Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft-tissue infections proven to be caused by methicillin-resistant Staphylococcus aureus Am J Surg 199 2010 804 816
-
(2010)
Am J Surg
, vol.199
, pp. 804-816
-
-
Itani, K.M.1
Dryden, M.S.2
Bhattacharyya, H.3
Kunkel, M.J.4
Baruch, A.M.5
Weigelt, J.A.6
-
43
-
-
84856937734
-
Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: A randomized, controlled study
-
R.G. Wunderink, M.S. Niederman, M.H. Kollef, A.F. Shorr, M.J. Kunkel, and A. Baruch et al. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study Clin Infect Dis 54 2012 621 629
-
(2012)
Clin Infect Dis
, vol.54
, pp. 621-629
-
-
Wunderink, R.G.1
Niederman, M.S.2
Kollef, M.H.3
Shorr, A.F.4
Kunkel, M.J.5
Baruch, A.6
-
44
-
-
13444257356
-
Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by Gram-positive pathogens
-
I. Raad, R. Darouiche, J. Vazquez, A. Lentnek, R. Hachem, and H. Hanna et al. Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by Gram-positive pathogens Clin Infect Dis 40 2005 374 380
-
(2005)
Clin Infect Dis
, vol.40
, pp. 374-380
-
-
Raad, I.1
Darouiche, R.2
Vazquez, J.3
Lentnek, A.4
Hachem, R.5
Hanna, H.6
-
45
-
-
84896494385
-
-
Pharmaceuticals For Children Act Of 2007 B.
-
Best Pharmaceuticals for Children Act of 2007 Public Law: 110th Congress 2007
-
(2007)
Public Law: 110th Congress
-
-
-
46
-
-
84896494664
-
-
Research Equity Act Of 2007 P.
-
Pediatric Research Equity Act of 2007 Public Law: 110th Congress 2007
-
(2007)
Public Law: 110th Congress
-
-
-
49
-
-
84864497515
-
Pediatric versus adult drug trials for conditions with high pediatric disease burden
-
F.T. Bourgeois, S. Murthy, C. Pinto, K.L. Olson, J.P. Ioannidis, and K.D. Mandl Pediatric versus adult drug trials for conditions with high pediatric disease burden Pediatrics 130 2012 285 292
-
(2012)
Pediatrics
, vol.130
, pp. 285-292
-
-
Bourgeois, F.T.1
Murthy, S.2
Pinto, C.3
Olson, K.L.4
Ioannidis, J.P.5
Mandl, K.D.6
-
50
-
-
79952094973
-
The quality of registration of clinical trials
-
R.F. Viergever, and D. Ghersi The quality of registration of clinical trials PLoS One 6 2011 e14701
-
(2011)
PLoS One
, vol.6
, pp. 14701
-
-
Viergever, R.F.1
Ghersi, D.2
-
51
-
-
3142559736
-
Determining the reporting quality of RCTs in clinical pharmacology
-
Erratum in: Br J Clin Pharmacol 2004;58:102
-
E. Mills, Y.K. Loke, P. Wu, V.M. Montori, D. Perri, and D. Moher et al. Determining the reporting quality of RCTs in clinical pharmacology Br J Clin Pharmacol 58 2004 61 65 Erratum in: Br J Clin Pharmacol 2004;58:102
-
(2004)
Br J Clin Pharmacol
, vol.58
, pp. 61-65
-
-
Mills, E.1
Loke, Y.K.2
Wu, P.3
Montori, V.M.4
Perri, D.5
Moher, D.6
-
52
-
-
79952267051
-
The ClinicalTrials.gov results database - Update and key issues
-
D.A. Zarin, T. Tse, R.J. Williams, R.M. Califf, and N.C. Ide The ClinicalTrials.gov results database - update and key issues N Engl J Med 364 2011 852 860
-
(2011)
N Engl J Med
, vol.364
, pp. 852-860
-
-
Zarin, D.A.1
Tse, T.2
Williams, R.J.3
Califf, R.M.4
Ide, N.C.5
|